Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.

van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J.

Lancet. 2019 Nov 11. pii: S0140-6736(19)32534-6. doi: 10.1016/S0140-6736(19)32534-6. [Epub ahead of print]

PMID:
31732180
2.

The Pathogenesis of Ankylosing Spondylitis: an Update.

Pedersen SJ, Maksymowych WP.

Curr Rheumatol Rep. 2019 Nov 11;21(10):58. doi: 10.1007/s11926-019-0856-3. Review.

PMID:
31712904
3.

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).

Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS; COAST-V and COAST-W Study Groups.

Ann Rheum Dis. 2019 Nov 4. pii: annrheumdis-2019-216118. doi: 10.1136/annrheumdis-2019-216118. [Epub ahead of print]

4.

The role of imaging in the diagnosis and management of axial spondyloarthritis.

Maksymowych WP.

Nat Rev Rheumatol. 2019 Nov;15(11):657-672. doi: 10.1038/s41584-019-0309-4. Epub 2019 Oct 7. Review.

PMID:
31591500
5.

Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort.

Sepriano A, Ramiro S, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Elkayam O, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Landewé R, Maksymowych WP.

J Rheumatol. 2019 Sep 15. pii: jrheum.190303. doi: 10.3899/jrheum.190303. [Epub ahead of print]

PMID:
31523049
6.

The International RA BIODAM Cohort for Validation of Soluble Biomarkers in Rheumatoid Arthritis: Cohort Description.

Maksymowych WP, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Lambert RG, Elkayam O, Ramiro S, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Allaart R, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Sepriano A, Landewé R.

J Rheumatol. 2019 Sep 1. pii: jrheum.190302. doi: 10.3899/jrheum.190302. [Epub ahead of print]

PMID:
31474600
7.

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L.

Arthritis Rheumatol. 2019 Oct;71(10):1599-1613. doi: 10.1002/art.41042. Epub 2019 Aug 22.

PMID:
31436036
8.

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L.

Arthritis Care Res (Hoboken). 2019 Oct;71(10):1285-1299. doi: 10.1002/acr.24025. Epub 2019 Aug 21.

PMID:
31436026
9.

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group.

Maksymowych WP, Lambert RG, Østergaard M, Pedersen SJ, Machado PM, Weber U, Bennett AN, Braun J, Burgos-Vargas R, de Hooge M, Deodhar AA, Eshed I, Jurik AG, Hermann KA, Landewé RB, Marzo-Ortega H, Navarro-Compán V, Poddubnyy D, Reijnierse M, Rudwaleit M, Sieper J, Van den Bosch FE, van der Heijde D, van der Horst-Bruinsma IE, Wichuk S, Baraliakos X.

Ann Rheum Dis. 2019 Nov;78(11):1550-1558. doi: 10.1136/annrheumdis-2019-215589. Epub 2019 Aug 17.

PMID:
31422357
10.

Is There a Role for MRI to Establish Treatment Indications and Effectively Monitor Response in Patients with Axial Spondyloarthritis?

Schwartzman M, Maksymowych WP.

Rheum Dis Clin North Am. 2019 Aug;45(3):341-358. doi: 10.1016/j.rdc.2019.04.009. Epub 2019 Jun 5. Review.

PMID:
31277748
11.

GRAPPA 2018 Project Report.

Goel N, FitzGerald O, Gladman DD, Helliwell PS, Kavanaugh A, Maksymowych WP, Mease PJ, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2019 Jun;95:54-57. doi: 10.3899/jrheum.190121.

PMID:
31154406
12.

Commentary on: reporting in axial spondyloarthritis: proposal for an MRI reporting system.

O'Neill J, Carmona R, Maksymowych WP.

Clin Radiol. 2019 Sep;74(9):684-691. doi: 10.1016/j.crad.2019.04.011. Epub 2019 May 22. No abstract available.

PMID:
31128852
13.

Drs. Lambert and Maksymowych reply.

Lambert RG, Maksymowych WP.

J Rheumatol. 2019 May;46(5):542. doi: 10.3899/jrheum.181215. No abstract available.

PMID:
31043501
14.

Biomarkers for Diagnosis of Axial Spondyloarthritis, Disease Activity, Prognosis, and Prediction of Response to Therapy.

Maksymowych WP.

Front Immunol. 2019 Mar 7;10:305. doi: 10.3389/fimmu.2019.00305. eCollection 2019. Review.

15.

Identification of fibrinogen as a natural inhibitor of MMP-2.

Sarker H, Hardy E, Haimour A, Maksymowych WP, Botto LD, Fernandez-Patron C.

Sci Rep. 2019 Mar 13;9(1):4340. doi: 10.1038/s41598-019-40983-y.

16.

A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.

Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landewé R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D.

Arthritis Rheumatol. 2019 Jul;71(7):1101-1111. doi: 10.1002/art.40866. Epub 2019 May 28.

17.

OMERACT Hip Inflammation Magnetic Resonance Imaging Scoring System (HIMRISS) Assessment in Longitudinal Study.

Jaremko JL, Lambert RGW, Pedersen SJ, Weber U, Lindsay D, Al-Ani Z, Steer K, Pianta M, Wichuk S, Maksymowych WP.

J Rheumatol. 2019 Sep;46(9):1239-1242. doi: 10.3899/jrheum.181043. Epub 2019 Feb 15.

PMID:
30770513
18.

Development and Validation of an OMERACT MRI Whole-Body Score for Inflammation in Peripheral Joints and Entheses in Inflammatory Arthritis (MRI-WIPE).

Krabbe S, Eshed I, Gandjbakhch F, Pedersen SJ, Bird P, Mathew AJ, Lambert RG, Maksymowych WP, Glinatsi D, Stoenoiu MS, Poggenborg R, Jans L, Jaremko JL, Herregods N, Foltz V, Conaghan PG, Althoff CE, Paschke J, Peterfy C, Hermann KA, Østergaard M; for the OMERACT MRI in Arthritis Working Group.

J Rheumatol. 2019 Sep;46(9):1215-1221. doi: 10.3899/jrheum.181084. Epub 2019 Feb 15.

PMID:
30770508
19.

Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Imaging Score (OMERACT JAMRIS-SIJ).

Otobo TM, Conaghan PG, Maksymowych WP, van der Heijde D, Weiss P, Sudol-Szopinska I, Herregods N, Jaremko JL, Meyers AB, Rumsey D, Inarejos EC, Kirkhus E, Stimec J, Panwar J, Thorpe K, Jans L, van Rossum MA, Tolend M, Perez M, Tzaribachev N, Sandhya P, Tse S, Simone A, Swami VG, Touma Z, Lambert R, Doria AS.

J Rheumatol. 2019 Sep;46(9):1192-1197. doi: 10.3899/jrheum.181115. Epub 2019 Feb 15.

PMID:
30770500
20.

The OMERACT MRI in Enthesitis Initiative: Definitions of Key Pathologies, Suggested MRI Sequences, and a Novel Heel Enthesitis Scoring System.

Mathew AJ, Krabbe S, Eshed I, Gandjbakhch F, Bird P, Pedersen SJ, Stoenoiu MS, Foltz V, Glinatsi D, Lambert RG, Hermann KGA, Maksymowych WP, Haugen IK, Jaremko JL, Poggenborg RP, Paschke J, Laredo JD, Carron P, Conaghan PG, Østergaard M.

J Rheumatol. 2019 Sep;46(9):1232-1238. doi: 10.3899/jrheum.181093. Epub 2019 Feb 1.

PMID:
30709961
21.

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison.

Maksymowych WP, Strand V, Nash P, Yazici Y, Thom H, Hunger M, Kalyvas C, Gandhi KK, Porter B, Jugl SM.

Eur J Rheumatol. 2018 Dec;5(4):216-223. doi: 10.5152/eurjrheum.2018.18162. Epub 2018 Oct 30.

22.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.

van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, Abi-Saab W, Tasset C, Meuleners L, Besuyen R, Hendrikx T, Mozaffarian N, Liu K, Greer JM, Deodhar A, Landewé R.

Lancet. 2018 Dec 1;392(10162):2378-2387. doi: 10.1016/S0140-6736(18)32463-2. Epub 2018 Oct 22.

23.

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group.

Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22.

PMID:
30360964
24.

Beyond the TNF-α Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology.

Pedersen SJ, Maksymowych WP.

Drugs. 2018 Sep;78(14):1397-1418. doi: 10.1007/s40265-018-0971-x. Review.

PMID:
30171593
25.

Use of disease-modifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infection in ankylosing spondylitis.

Moura CS, Rahme E, Maksymowych WP, Abrahamowicz M, Bessette L, Bernatsky S.

Scand J Rheumatol. 2019 Mar;48(2):121-127. doi: 10.1080/03009742.2018.1470253. Epub 2018 Aug 16.

PMID:
30112959
26.

Comparing Strategies Targeting Osteoporosis to Prevent Fractures After an Upper Extremity Fracture (C-STOP Trial): A Randomized Controlled Trial.

Majumdar SR, McAlister FA, Johnson JA, Rowe BH, Bellerose D, Hassan I, Lier DA, Li S, Maksymowych WP, Menon M, Russell AS, Wirzba B, Beaupre LA.

J Bone Miner Res. 2018 Dec;33(12):2114-2121. doi: 10.1002/jbmr.3557. Epub 2018 Aug 22.

PMID:
30040140
27.

Radiographs in screening for sacroiliitis in children: what is the value?

Weiss PF, Xiao R, Brandon TG, Biko DM, Maksymowych WP, Lambert RG, Jaremko JL, Chauvin NA.

Arthritis Res Ther. 2018 Jul 11;20(1):141. doi: 10.1186/s13075-018-1642-8.

28.

Feasibility and Reliability of the Spondyloarthritis Research Consortium of Canada Sacroiliac Joint Structural Score in Children.

Weiss PF, Maksymowych WP, Lambert RG, Jaremko JL, Biko DM, Paschke J, Brandon TG, Xiao R, Chauvin NA.

J Rheumatol. 2018 Oct;45(10):1411-1417. doi: 10.3899/jrheum.171329. Epub 2018 Jun 15.

PMID:
29907669
29.

Diffusion-weighted Imaging in Axial Spondyloarthritis: A Measure of Effusion or Does It Elicit Confusion?

Lambert RG, Maksymowych WP.

J Rheumatol. 2018 Jun;45(6):729-730. doi: 10.3899/jrheum.171479. No abstract available.

PMID:
29858453
30.

Options for Assessing Joints and Entheses in Psoriatic Arthritis by Ultrasonography and Magnetic Resonance Imaging: How to Move Forward.

Eder L, Aydin SZ, Kaeley GS, Maksymowych WP, Østergaard M.

J Rheumatol Suppl. 2018 Jun;94:44-47. doi: 10.3899/jrheum.180140.

PMID:
29858354
31.

Effectiveness, Complications, and Costs of Rheumatoid Arthritis Treatment with Biologics in Alberta: Experience of Indigenous and Non-indigenous Patients.

Barnabe C, Zheng Y, Ohinmaa A, Crane L, White T, Hemmelgarn B, Kaplan GG, Martin L, Maksymowych WP.

J Rheumatol. 2018 Oct;45(10):1344-1352. doi: 10.3899/jrheum.170779. Epub 2018 Jun 1.

PMID:
29858236
32.

Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients.

Maksymowych WP, van der Heijde D, Baraliakos X, Deodhar A, Sherlock SP, Li D, Fleishaker D, Hendrikx T, Kanik KS.

Rheumatology (Oxford). 2018 Aug 1;57(8):1390-1399. doi: 10.1093/rheumatology/key104.

33.

Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.

van der Heijde D, Sieper J, Maksymowych WP, Lambert RG, Chen S, Hojnik M, Anderson JK, Pangan AL.

Arthritis Res Ther. 2018 Mar 27;20(1):61. doi: 10.1186/s13075-018-1556-5.

34.

Feasibility and reliability of the Spondyloarthritis Research Consortium of Canada sacroiliac joint inflammation score in children.

Weiss PF, Maksymowych WP, Lambert RG, Jaremko JL, Biko DM, Paschke J, Brandon TG, Xiao R, Chauvin NA.

Arthritis Res Ther. 2018 Mar 22;20(1):56. doi: 10.1186/s13075-018-1543-x.

35.

Inflammatory and structural changes in vertebral bodies and posterior elements of the spine in axial spondyloarthritis: construct validity, responsiveness and discriminatory ability of the anatomy-based CANDEN scoring system in a randomised placebo-controlled trial.

Krabbe S, Sørensen IJ, Jensen B, Møller JM, Balding L, Madsen OR, Lambert RGW, Maksymowych WP, Pedersen SJ, Østergaard M.

RMD Open. 2018 Mar 16;4(1):e000624. doi: 10.1136/rmdopen-2017-000624. eCollection 2018.

36.

Patient-reported Outcomes, Resource Use, and Social Participation of Patients with Rheumatoid Arthritis Treated with Biologics in Alberta: Experience of Indigenous and Non-indigenous Patients.

Barnabe C, Crane L, White T, Hemmelgarn B, Kaplan GG, Martin L, Maksymowych WP.

J Rheumatol. 2018 Jun;45(6):760-765. doi: 10.3899/jrheum.170778. Epub 2018 Feb 15.

PMID:
29449496
37.

Spondyloarthritis: Low-dose CT for spondyloarthritis - a brilliant new chapter?

Maksymowych WP, Lambert RG.

Nat Rev Rheumatol. 2018 Mar;14(3):130-131. doi: 10.1038/nrrheum.2018.4. Epub 2018 Jan 25. No abstract available.

PMID:
29367690
38.

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.

van der Heijde D, Baraliakos X, Hermann KA, Landewé RBM, Machado PM, Maksymowych WP, Davies OR, de Peyrecave N, Hoepken B, Bauer L, Nurminen T, Braun J.

Ann Rheum Dis. 2018 May;77(5):699-705. doi: 10.1136/annrheumdis-2017-212377. Epub 2018 Jan 17.

39.

Sacroiliac Joint Magnetic Resonance Imaging in Asymptomatic Patients with Recurrent Acute Anterior Uveitis: A Proof-of-concept Study.

Oliveira TL, Maksymowych WP, Lambert RGW, Muccioli C, Fernandes ARC, Pinheiro MM.

J Rheumatol. 2017 Dec;44(12):1833-1840. doi: 10.3899/jrheum.170036. Epub 2017 Nov 1.

PMID:
29093157
40.

Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis.

Dougados M, Maksymowych WP, Landewé RBM, Moltó A, Claudepierre P, de Hooge M, Lambert RG, Bonin R, Bukowski JF, Jones HE, Logeart I, Pedersen R, Szumski A, Vlahos B, van der Heijde D.

Ann Rheum Dis. 2018 Feb;77(2):221-227. doi: 10.1136/annrheumdis-2017-212008. Epub 2017 Sep 29.

41.

Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis.

Maksymowych WP, Wichuk S, Dougados M, Jones HE, Pedersen R, Szumski A, Marshall L, Bukowski JF, Lambert RG.

Ann Rheum Dis. 2018 Jan;77(1):78-84. doi: 10.1136/annrheumdis-2017-211605. Epub 2017 Sep 29.

42.

Limited reliability of radiographic assessment of spinal progression in ankylosing spondylitis.

Aydin SZ, Kasapoglu Gunal E, Kurum E, Akar S, Mungan HE, Alibaz-Oner F, Lambert RG, Atagunduz P, Marzo Ortega H, McGonagle D, Maksymowych WP.

Rheumatology (Oxford). 2017 Dec 1;56(12):2162-2169. doi: 10.1093/rheumatology/kex321.

PMID:
28968836
43.

An update on biomarker discovery and use in axial spondyloarthritis.

Maksymowych WP.

Expert Rev Mol Diagn. 2017 Nov;17(11):965-974. doi: 10.1080/14737159.2017.1381562. Epub 2017 Sep 22. Review.

PMID:
28920498
44.

Hip Inflammation MRI Scoring System (HIMRISS) to predict response to hyaluronic acid injection in hip osteoarthritis.

Deseyne N, Conrozier T, Lellouche H, Maillet B, Weber U, Jaremko JL, Paschke J, Epstein J, Maksymowych WP, Loeuille D.

Joint Bone Spine. 2018 Jul;85(4):475-480. doi: 10.1016/j.jbspin.2017.08.004. Epub 2017 Sep 8.

PMID:
28893678
45.

Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis.

Braun J, Baraliakos X, Hermann KG, Landewé R, Machado PM, Maksymowych WP, Davies O, Hoepken B, Nurminen T, Stach C, van der Heijde D.

RMD Open. 2017 Apr 24;3(1):e000430. doi: 10.1136/rmdopen-2017-000430. eCollection 2017.

46.

Validation of a Knowledge Transfer Tool According to the OMERACT Filter: Does Web-based Real-time Iterative Calibration Enhance the Evaluation of Bone Marrow Lesions in Hip Osteoarthritis?

Jaremko JL, Azmat O, Lambert RGW, Bird P, Haugen IK, Jans L, Weber U, Winn N, Zubler V, Maksymowych WP.

J Rheumatol. 2017 Nov;44(11):1713-1717. doi: 10.3899/jrheum.161101. Epub 2017 Jul 1.

PMID:
28668804
47.

Whole-body Magnetic Resonance Imaging in Inflammatory Arthritis: Systematic Literature Review and First Steps Toward Standardization and an OMERACT Scoring System.

Østergaard M, Eshed I, Althoff CE, Poggenborg RP, Diekhoff T, Krabbe S, Weckbach S, Lambert RGW, Pedersen SJ, Maksymowych WP, Peterfy CG, Freeston J, Bird P, Conaghan PG, Hermann KG.

J Rheumatol. 2017 Nov;44(11):1699-1705. doi: 10.3899/jrheum.161114. Epub 2017 Jun 15. Review.

48.

MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation.

Maksymowych WP, Wichuk S, Dougados M, Jones H, Szumski A, Bukowski JF, Marshall L, Lambert RG.

Arthritis Res Ther. 2017 Jun 6;19(1):126. doi: 10.1186/s13075-017-1342-9.

49.

Clinical effectiveness and safety of leflunomide in inflammatory arthritis: a report from the RAPPORT database with supporting patient survey.

Schultz M, Keeling SO, Katz SJ, Maksymowych WP, Eurich DT, Hall JJ.

Clin Rheumatol. 2017 Jul;36(7):1471-1478. doi: 10.1007/s10067-017-3687-5. Epub 2017 May 27.

PMID:
28550389
50.

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.

van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A.

Rheumatology (Oxford). 2017 Sep 1;56(9):1498-1509. doi: 10.1093/rheumatology/kex174.

Supplemental Content

Loading ...
Support Center